Compton Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Compton Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,765	Closed	-$222K	–	137
2015 Q2	$222K	Hold	3,765	–	–	0.12%	133
2015 Q1	$235K	Hold	3,765	–	–	0.13%	131
2014 Q4	$216K	Buy	+3,765	New	+$210K	0.12%	135
2014 Q2	–	Sell	-4,206	Closed	-$222K	–	146
2014 Q1	$222K	Buy	+4,206	New	+$194K	0.13%	130
2013 Q4	–	Sell	-12,186	Closed	-$460K	–	145
2013 Q3	$460K	Sell	12,186 -1,420	-10%	-$55.4K	0.28%	85
2013 Q2	$533K	Buy	+13,606	New	+$530K	0.33%	79

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Compton Capital Management's TEVA Position: Q3 2015 in Review

Compton Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 3,765 shares — an estimated $222K sold.

Compton Capital Management first reported a position in TEVA in Q2 2013 and held it in 6 quarters. The position peaked at $533K in Q2 2013. 824 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

Compton Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Compton Capital Management sold 3,765 Teva Pharmaceuticals shares in Q3 2015, an estimated $222K.
Compton Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Compton Capital Management's Teva Pharmaceuticals position peaked at $533K in Q2 2013.
824 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on Compton Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.